

**R.M. Huber:** has received support from the following companies: AstraZeneca, Boehringer Ingelheim, Lilly, Merck, Pfizer, Pierre-Fabre and Roche (reimbursement for attending symposia, and fees for speaking, organising education and consulting).

**M. Reck:** has served as a compensated member on an advisory board of Hoffmann-La Roche, Lilly, Daiichi-Sankyo, BMS and AstraZeneca. He has received honoraria for lectures from Hoffmann-La Roche, Lilly, Daiichi-Sankyo and AstraZeneca.

**M. Thomas:** has received speaker's honoraria from Merck.

Editorial assistance for this manuscript, provided International Medical Press, was funded by Merck KGaA, Darmstadt, Germany.